pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Ultragenyx Pharmaceutical Inc. ($RARE) · news · pharmadog
← back to Ultragenyx Pharmaceutical Inc.
News mentioning $RARE
825
stories
23d
Novartis drags peers down with triple asset stumble
biospace
23d
Novartis drags peers down with triple asset failure
biospace
24d
STAT+: An AI tool aims to catch harder-to-detect heart attacks in EKGs
stat
24d
Mikhail, Davis embody the FDA’s stabilization, Seehafer signals AI revolution is coming
biospace
24d
Evergreen Fresh Sprouts LLC Recalls Broccoli Sprouts Because of Possible Health Risk
fda recalls
24d
Platinum-based chemotherapy in childhood causes mutations that age the liver
stat
24d
FDA places partial hold on Biohaven’s epilepsy drug
biopharma dive
24d
Andy Plump, architect of Takeda’s R&D overhaul, to retire next year
biopharma dive
24d
Biohaven takes another hit as FDA pauses enrollment in pivotal trials for embattled epilepsy drug
biospace
24d
Encoded raises $275M series F for Dravet syndrome gene therapy
biospace
24d
STAT+: What to expect from UniQure’s upcoming Huntington’s gene therapy readout
stat
24d
Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters
fiercebiotech
25d
Encoded closes $275M Series F for Dravet syndrome drug
endpoints
25d
FDA gains ‘continuity’ as Mikhail, Davis named permanent CBER, CDER leaders
biopharma dive
25d
Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease
biospace
25d
GV-backed Encoded gains $275M to advance Dravet drug, scale genetic med manufacturing
fiercebiotech
26d
Steady stream of crossover rounds stock biotech's IPO pipeline
biospace
26d
Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy
biopharma dive
26d
Pharvaris' stock jumps on pivotal success in rare genetic disease
endpoints
26d
Structure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data drop
biospace
26d
STAT+: Health care features prominently in Democrats’ agenda
stat
26d
STAT+: Pharmalittle: We’re reading about another Novartis trial failure, a Novo Nordisk setback, and more
stat
26d
Novartis RNA drug falls short in rare muscle disease study
biopharma dive
26d
Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints
biospace
26d
STAT+: Inhibrx claims first win for long-sought immunotherapy target
stat
26d
BrainChild Bio targets deadly pediatric brain cancer with $116M series A
biospace
26d
BrainChild hauls in $116M to make cell therapies for childhood brain cancers
biopharma dive
26d
STAT+: Roivant lung disease drug hits mid-stage study goals
stat
26d
FDA approves AstraZeneca’s Etcamah, opening ctDNA-guided treatment paradigm in breast cancer
fiercebiotech
26d
Pharvaris' latest phase 3 win builds case for HAE drug with FDA verdict pending
fiercebiotech
← prev
page 6 of 28
next →
